GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, with many patients quitting GLP-1 treatment within a year.

Wellness influencer Janelle Rohner has seen the internet’s criticism after revealing she micro-dosed GLP-1 to lose weight.

She lost 250 pounds and thought her journey was over... but then she discovered something most people don't talk about.

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...